HER2-Positive Early Stage Breast Cancer Completed Phase 3 Trials for Trastuzumab (DB00072)

Also known as: HER2-Positive Early Breast Cancer / HER2-positive early-stage breast cancer / Early Stage HER2+ Breast Cancer / HER2 Positive Early Breast Cancer

DBCOND0063722 (HER2-Positive Early Stage Breast Cancer)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03989037A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast CancerTreatment